[Form 4] HARVARD BIOSCIENCE INC Insider Trading Activity

Rhea-AI Filing Summary

Stephen DeNelsky, a director of Harvard Bioscience, Inc. (HBIO), reported an award of 110,000 restricted stock units on 09/05/2025. The Form 4 shows the units were recorded as acquired at a price of $0.00 and are held directly, bringing the reporting person’s beneficial ownership following the transaction to 110,000 shares. The filing explains these restricted stock units fully vest on 09/05/2026. The form is signed by the reporting person on 10/07/2025.

Positive

• 110,000 RSU award creates direct alignment between the director and shareholders
• One‑year vesting (vesting on 09/05/2026) encourages retention through the next year
• Direct ownership recorded immediately increases reported insider stake to 110,000 shares

Negative

• Potential dilution of 110,000 shares when RSUs vest and convert to common stock
• No disclosure in this filing of total shares outstanding, so dilution impact is unclear

Insights

Compensation Governance Analyst

Director awarded time‑vested RSUs aligning interests to long‑term performance.

The grant of 110,000 restricted stock units vests in one year on 09/05/2026, creating a direct equity link between the director and future share performance. Time‑vesting is a common mechanism to retain directors and align their incentives with shareholders.

Key dependencies include share price at vesting and any forfeiture conditions; the award is recorded at a $0.00 acquisition price in the filing. Investors may track the director’s vested holdings around 09/05/2026 for potential sales or insider signals.

Equity Dilution Specialist

Large single grant could modestly increase outstanding shares when vested.

The filing documents 110,000 RSUs that convert into common shares upon vesting, which will increase outstanding share count by that amount unless settled in cash. The immediate reported beneficial ownership is 110,000 shares held directly.

Materiality depends on current total shares outstanding (not provided in the filing); monitor outstanding share figures and post‑vesting filings around 09/05/2026 to quantify dilution and potential selling activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DENELSKY STEPHEN J

(Last) (First) (Middle)

C/O HARVARD BIOSCIENCE, INC.

84 OCTOBER HILL ROAD

(Street)

HOLLISTON MA 01746

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HARVARD BIOSCIENCE INC [ HBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		A		110,000(1)	A	$0.00	110,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of 110,000 restricted stock units that fully vest on September 5, 2026.

	/s/ Stephen DeNelsky	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Harvard Bioscience insider Stephen DeNelsky report on Form 4 (HBIO)?

The Form 4 reports an award of 110,000 restricted stock units acquired on 09/05/2025, recorded at a price of $0.00, with direct beneficial ownership of 110,000 shares.

When do the 110,000 RSUs vest for HBIO insider Stephen DeNelsky?

The filing states the restricted stock units fully vest on 09/05/2026.

Did the Form 4 show any sale or disposition of HBIO shares by the reporting person?

No. The Form 4 shows an acquisition (code A) of 110,000 RSUs and no dispositions; the price is listed as $0.00.

How does this Form 4 affect outstanding shares for HBIO?

The RSUs will convert to common shares upon vesting, adding up to 110,000 shares to outstanding count unless settled otherwise; the filing does not disclose current total shares outstanding.

When was the Form 4 signed by the reporting person?

The Form 4 is signed by Stephen DeNelsky on 10/07/2025.